

Acute liver failure with thrombotic microangiopathy due to sodium valproate toxicity: A case report

Xuan Mei, Hai-Cong Wu, Mei Ruan, Li-Rong Cai

ORCID number: Xuan Mei 0000-0002-4096-3894; Hai-Cong Wu 0000-0001-8273-7548; Mei Ruan 0000-0001-8523-1622; Li-Rong Cai 0000-0002-9965-1676.

Author contributions: Mei X analyzed the data, reviewed the literature, and wrote the manuscript; Ruan M and Cai LR performed the diagnostic investigations and treatments, and collected the data; Wu HC followed the patient and reviewed and revised the manuscript; all authors have read and approved the final manuscript.

Informed consent statement:

Informed written consent was obtained from the patient's family for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest to report.

CARE Checklist (2016) statement:

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in

Xuan Mei, Hai-Cong Wu, Li-Rong Cai, Department of Hepatobiliary Internal Medicine, The 900th Hospital of PLA Joint Logistics Support Force, Fuzhou 350025, Fujian Province, China

Mei Ruan, Department of Hepatobiliary Internal Medicine, The third affiliated people's hospital of Fujian University of traditional Chinese medicine, Fuzhou 350100, Fujian Province, China

Corresponding author: Hai-Cong Wu, MS, Attending Doctor, Department of Hepatobiliary Internal Medicine, The 900th Hospital of PLA Joint Logistics Support Force, No. 156 North of West Second Ring Road, Gulou District, Fuzhou 350025, Fujian Province, China.
847614051@qq.com

Abstract

BACKGROUND

Sodium valproate is widely used in the treatment of epilepsy in clinical practice. Most adverse reactions to sodium valproate are mild and reversible, while serious idiosyncratic side effects are becoming apparent, particularly hepatotoxicity. Herein, we report a case of fatal acute liver failure (ALF) with thrombotic microangiopathy (TMA) caused by treatment with sodium valproate in a patient following surgery for meningioma.

CASE SUMMARY

A 42-year-old man who received antiepileptic treatment with sodium valproate after surgery for meningioma exhibited extreme fatigue, severe jaundice accompanied by oliguria, soy sauce-colored urine, and ecchymosis. His postoperative laboratory values indicated a rapid decreased platelet count and hemoglobin level, severe liver and kidney dysfunction, and disturbance of the coagulation system. He was diagnosed with drug-induced liver failure combined with TMA. After plasma exchange combined with hemoperfusion, pulse therapy with high-dose methylprednisolone, and blood transfusion, his liver function deteriorated, and finally, he died.

CONCLUSION

ALF with TMA is a rare and fatal adverse reaction of sodium valproate which needs to be highly valued.

Key Words: Sodium valproate; Drug-induced liver injury; Thrombotic microangiopathy; Plasma exchange; Organ transplantation; Case report

accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: China

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B, B
Grade C (Good): C, C
Grade D (Fair): D
Grade E (Poor): E

Received: January 10, 2021

Peer-review started: January 10, 2021

First decision: February 11, 2021

Revised: February 21, 2021

Accepted: April 2, 2021

Article in press: April 2, 2021

Published online: June 16, 2021

P-Reviewer: Abe Y, Fahrner R, Maslennikov R, Paramesh AS, Skok P

S-Editor: Liu M

L-Editor: Wang TQ

P-Editor: Li JH



©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Sodium valproate is widely used in the treatment of epilepsy in clinical practice although it has potential hepatotoxicity. Herein, we report a case of fatal acute liver failure (ALF) with thrombotic microangiopathy (TMA) caused by sodium valproate treatment. A history of chronic hepatitis B virus infection or combination therapy with sodium valproate and carbapenem may increase the risk of ALF. The combination therapy of plasma exchange, glucocorticoid, and supportive therapy is essential for TMA. Organ transplantation at the early stage of the disease may be the first choice for critically ill patients. Our case report can facilitate further studies on the diagnosis and therapy of ALF with TMA.

Citation: Mei X, Wu HC, Ruan M, Cai LR. Acute liver failure with thrombotic microangiopathy due to sodium valproate toxicity: A case report. *World J Clin Cases* 2021; 9(17): 4310-4317

URL: <https://www.wjgnet.com/2307-8960/full/v9/i17/4310.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v9.i17.4310>

INTRODUCTION

Sodium valproate is one of the common fatty-acid antiepileptic drugs in the current daily clinical routine[1]. It is effective in the treatment of various types of epilepsy to different extents. With extensive application in the clinic, an increasing number of adverse reactions of sodium valproate have been reported[2,3]. Adverse reactions involve multiple organ systems, such as the hematological system, nervous system, and digestive system[4]. Sodium valproate has been the most common drug to induce liver injury among all antiepileptic drugs in recent years[5]. The proportion of patients with hepatic dysfunction caused by sodium valproate has been reported to be as high as 5%-10%[3]. Symptoms in most patients are temporary and reversible, while a minority can be fatal, and some patients can develop drug-induced thrombotic microangiopathy (DI-TMA)[6]. We report a case of sodium valproate-induced acute liver failure (ALF) with thrombotic microangiopathy (TMA), which has not been reported previously.

CASE PRESENTATION

Chief complaints

A 42-year-old male was admitted to the Department of Hepatobiliary Internal Medicine 10 d following surgery for meningioma with fatigue and abdominal distension for 1 d.

History of present illness

Ten days before admission to the Department of Hepatobiliary Internal Medicine, the patient underwent surgery for atypical meningioma (World Health Organization grade II) resection because of progressive deterioration of vision in the right eye for more than half a year and headache for more than one month. His preoperative hematological parameters were essentially normal: Hemoglobin (Hgb), 132 g/L (130-175 g/L); platelet (PLT) count $99 \times 10^9/L$ ($125-350 \times 10^9/L$); alanine aminotransferase (ALT), 34.7 U/L (7-50 U/L); aspartate aminotransferase (AST), 22.5 U/L (13-40 U/L); total bilirubin (TBIL), 12 $\mu\text{mol/L}$ ($< 21 \text{ mmol/L}$); direct bilirubin (DBIL), 2.7 $\mu\text{mol/L}$ ($< 5 \text{ mmol/L}$); indirect bilirubin (IBIL), 9.3 $\mu\text{mol/L}$ ($< 16 \text{ mmol/L}$); creatine kinase (CK), 86 U/L (26-174 U/L); lactate dehydrogenase (LDH), 226 U/L (109-245 U/L); serum creatinine (Scr), 94 $\mu\text{mol/L}$ (53-115 $\mu\text{mol/L}$); prothrombin time (PT), 11.9 s (9.8-12.1s); international normalized ratio (INR), 1.05 (0.82-1.15); D-dimer (D-D), 0.14 mg/L ($< 0.5 \text{ mg/L}$); fibrinogen (FIB), 2.48 g/L (2-4 g/L). Preoperative abdominal color Doppler ultrasound showed that his other organs were normal except a mildly coarse hepatic parenchymal echotexture. Cranial contrast-enhanced magnetic resonance imaging indicated the right sphenoid ridge meningioma (6.6 cm \times 5.5 cm). After the surgery, sodium valproate 1.2 g per day was used to treat secondary epilepsy. On postopera-

tive day 3, sodium valproate was increased to 1.6 g per day and was given for 7 d due to the exacerbation of secondary epilepsy. On postoperative day 5, the patient started to develop symptoms of cerebral edema with headaches and intermittent vomiting; therefore, methylprednisolone 1000 mg per day was given for 4 d (postoperative day 5 to day 8). During his surgical hospitalization, because of fever on postoperative day 1 and increased cerebrospinal fluid leukocytes on postoperative day 5, antibiotics were used for anti-infective therapy as follows: Ceftriaxone plus vancomycin (postoperative day 1 to day 4) and biapenem plus linezolid (postoperative day 5 to day 9). The major medications used in the patient during hospitalization are recorded in [Figure 1](#).

On postoperative day 9, the patient began to experience restlessness and progressive abdominal distension. His hematological parameters were as follows: Hgb, 103 g/L; PLT count, 109×10^9 /L; ALT, 5713.8 U/L; AST, 7329.5 U/L; TBIL, 71.7 $\mu\text{mol/L}$; DBIL, 33.6 $\mu\text{mol/L}$; IBIL, 38.1 $\mu\text{mol/L}$; CK, 3912 U/L; LDH, 7744 U/L; Scr, 80 $\mu\text{mol/L}$; PT, 18.3 s; INR, 1.63; and D-D, 10.63 mg/L. Then, he received treatment for liver protection, gastrointestinal motility promotion, and enema; however, he did not recover from aggravated abdominal distension and gradually developed sleepiness, fatigue, oliguria, soy sauce-colored urine, and jaundice. Therefore, sodium valproate was discontinued, and he was transferred to the Department of Hepatobiliary Internal Medicine for further treatment on postoperative day 10.

History of past illness

The patient was diagnosed with hepatitis B surface antigen (HBsAg) positivity without antiviral treatment for 3 years due to continuous normal hepatic function, and hepatitis B virus (HBV) DNA was < 500 IU/mL (< 500 IU/mL) during periodic re-examinations.

Personal and family history

The patient did not have a history of smoking or alcoholism or a remarkable family medical history.

Physical examination

The patient was in a somnolent state with myoclonic jerks in the upper limbs. His skin and sclera were severely yellow. Bilateral petechia and ecchymosis were noted both in the lower limbs and near the injection and puncture sites. His abdomen was distended, with tympanic percussion sounds.

Laboratory examinations

On postoperative day 10, the patient's laboratory data showed that his Hgb was 61 g/L, hematocrit was 18.3% (40%-50%), PLT count was 56×10^9 /L, D-D exceeded 35.2 mg/L, PT was 76.9 s, INR was 7.25, and FIB was 0.88 g/L. His reticulocyte percentage was up to 4.5% (0.5%-1.5%). Although the urinalysis revealed that his urine was positive for occult blood and urobilinogen, there were no fragmented erythrocytes on the peripheral blood smear. His ALT was 16144.0 U/L, AST exceeded 21000.0 U/L, CK was 4471.0 U/L, LDH was 21962.0 U/L, TBIL was 144.1 $\mu\text{mol/L}$, DBIL was 19.6 $\mu\text{mol/L}$, IBIL was 124.5 $\mu\text{mol/L}$, and Scr was 255.0 $\mu\text{mol/L}$. HBV DNA, ceruloplasmin, and autoimmune antibodies in his serum were all negative. The hematological indices of the patient during hospitalization are shown in [Figure 2](#).

Imaging examinations

The morphology and density of the liver were normal on preoperative day 5. On postoperative day 9, geographical patterns of low-density shadow in the liver were demonstrated on computed tomography (CT), which suggested extensive hepatic necrosis. No noticeable abnormality was detected in the kidneys and spleen, but a small amount of pelvic and peritoneal effusions. The abdominal CT of the patient during hospitalization is shown in [Figure 3](#).

FINAL DIAGNOSIS

The patient was diagnosed with drug-induced liver injury (DILI) (hepatocellular type, acute, RUCAM score 6 (probable), level 5 severity of liver injury) complicated with TMA.




Figure 1 Major medications used in the patient during hospitalization. The dosage of the antibiotics are as follows: Ceftriaxone 2 g/q12h; vancomycin 1000 mg/q12h; biapenem 0.6 g/q12h; linezolid 600 mg/q12h.

TREATMENT

The patient was placed on the active waiting list for liver transplantation as soon as the diagnosis was made. Sequential plasma exchange (PE) with fresh frozen plasma and hemoperfusion were initiated immediately after admission. After the above therapy, the patient was still anuric, and continuous renal replacement therapy was performed. He underwent treatment with methylprednisolone 80 mg per day for 2 d on the basis of PE. Meanwhile, he was given human prothrombin complex and washed red blood cells to improve coagulation function and anemia. Polyene phosphatidylcholine, glutathione, ademetionine 1,4-butanedisulfonate, and ornithine aspartate were used to promote hepatic recovery.

OUTCOME AND FOLLOW-UP

After treatment, the patient's hemolysis was controlled, the color of his separated plasma gradually changed from red-brown to dark yellow, and the hemoglobin level did not decline. However, he was still in a persistent anuric and coma state, and there were no suitable liver or kidney sources for transplantation. Finally, the patient died in the early morning of postoperative day 12.

DISCUSSION

On the 9th postoperative day for meningioma, the patient developed ALF with extreme fatigue, severe jaundice, prolonged prothrombin time, and acute progressive hepatic coma. Although he was an HBsAg carrier, the HBV DNA in his serum was negative; thus, the possibility of liver injury caused by HBV reactivation can be excluded. In addition, the patient's history suggested no trauma, exertion, hyperthermia, or infections, which are common causes for liver failure, and his symptoms did not include myalgia, which is typical in rhabdomyolysis. Although he was on several medications during hospital stay, the major adverse effects did not include rhabdomyolysis. Therefore, the liver failure was not considered to be associated with rhabdomyolysis. Because his alcoholism history and hematological indices of autoimmune diseases were negative, we finally considered his ALF to be attributed to the drug.

Sodium valproate, vancomycin, and linezolid are the common drugs associated with DILI[5,7,8]. Among all the adverse reactions of vancomycin, most are rapid onset, and renal injury occurs more frequently than liver injury[9]. Common adverse reactions of linezolid include myelotoxicity and peripheral and optic neuropathy[10]. Studies show that liver injury induced by linezolid usually occurs after two weeks of medication, with a mild elevation of transaminase[11]. The characteristics of our patient who developed severe liver dysfunction after using linezolid for only 5 d were inconsistent with those reported in the literature. Liver injury is one of the most often reported adverse effects of sodium valproate because sodium valproate is metabolized by glucuronidation and mitochondrial beta-oxidation in the liver[5]. ALF due to sodium valproate can still be encountered in the clinic[12]. The RUCAM scoring table is recognized as the primary DILI causality assessment tool[13]. The RUCAM score of this patient was 6 (probable) when we completed the causality assessment for sodium




Figure 2 Hematological indices of the patient during hospitalization. A: Serum aminotransferase; B: Serum bilirubin; C: Renal function; D: Serum myocardial enzymes; E: Coagulation function; F: Routine blood parameters. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; Scr: Serum creatinine; BUN: Blood urea nitrogen; LDH: Lactate dehydrogenase; CK: Creatine kinase; PT: Prothrombin time; INR: International Normalized Ratio; D-D: D-dimer; FIB: Fibrinogen; Hgb: Hemoglobin; PLT: Platelet; HCT: Hematocrit.

valproate. Thus, we considered that his liver injury was induced by sodium valproate. Sodium valproate, as one of the most widely used broad-spectrum antiepileptic drugs, has been used as a first-line treatment in clinical practice[1]. It has the characteristics of high bioavailability, good tolerability, and remarkable efficacy except for a narrow therapeutic window[14]. A black box warning of severe hepatotoxicity with sodium valproate was published by the Food and Drug Administration[15]. The pathogenesis of the toxic effects of sodium valproate on the liver has not yet been fully elucidated. The obstacles of cytochrome P450 metabolism and β-oxidation in mitochondria are generally considered the major mechanisms of the hepatotoxicity of sodium valproate, while the former is an important factor for individual differences in liver injury. Studies have shown that risk factors for fatal liver failure caused by sodium valproate include age younger than 2 years, combination therapy with sodium valproate and other antiepileptic drugs, pregnancy, a history of liver diseases, and




Figure 3 Abdominal computed tomography of the patient during hospitalization. A: On preoperative day 5, the morphology and density of the liver were normal; B: On postoperative day 9, the density of several parts of the liver was low.

other neurological diseases[16,17]. It is controversial whether the liver injury induced by sodium valproate is related to the plasma concentration of sodium valproate. The research has shown that patients with high plasma concentrations of sodium valproate are more susceptible to liver injury than those with low plasma concentrations[18]. However, Ghozzi *et al*[19] supposed that liver injury is independent of the sodium valproate plasma concentration. However, there is currently no research on the correlation between HBV infection and liver injury induced by sodium valproate. Therefore, whether the fatal liver failure induced by sodium valproate in our patient is related to HBV infection needs further research.

Except for ALF, TMA should be considered in diagnosis. Generally, microangiopathic hemolytic anemia is a *sine qua non* for the diagnosis of TMA[20]. This patient exhibited anuria, hemoglobinuria, progressively decreased levels of hemoglobin and platelets, elevated proportion of reticulocytes, and significantly elevated bilirubin and D-D level during the early stage of his disease, which were consistent with the characteristics of TMA. However, no fragmented erythrocytes were observed on the peripheral blood smear either before or after PE. Cases of TMA without the presence of fragmented erythrocytes on the peripheral blood smear have been reported previously[21,22]. This patient responded to PE and methylprednisolone. Therefore, a diagnosis of TMA was suggested. As far as we are concerned, the presence of fragmented erythrocytes is essential for TMA diagnosis in most cases, but not all.

TMA is defined as a clinical syndrome characterized by thrombocytopenia, hemolytic anemia, and multiple organ dysfunction[21]. The microthrombosis of capillaries and arterioles is the typical pathological feature of TMA. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two clinical presentation forms of TMA. TTP mostly involves the nervous system, while there is a preponderance of renal injury in HUS patients. The etiology of TMA is multifactorial, including genetic factors and acquired risk factors. DI-TMA is a type of acquired TMA that is caused by multiple drugs, such as antitumor agents, antiplatelet drugs, and oral contraceptives. Studies show that DI-TMA occurs *via* two main mechanisms: Immune-mediated reactions or dose-dependent toxicity[23]. TMA mediated by dose-dependent reactions has a slow, progressive onset, while immune-mediated TMA has a rapid onset[21]. Our patient can be classified as having immune-mediated DI-TMA.

For the patient, it was inferred that sodium valproate plus carbapenem antibiotics might increase the risk of hemolysis, which could cause TMA. However, the period of the combination was short. König *et al*[24] showed that sodium valproate altered the exposure of immunoglobulin receptor and fatty acid content in the erythrocyte membrane. Alteration of the membrane fluidity and receptor proteins on the membrane would facilitate immunoglobulin to destruct erythrocytes. The correlation between destruction of erythrocytes and plasma level of sodium valproate remains unclear. Carbapenem antibiotics can reduce the plasma level of sodium valproate by inhibiting multidrug resistance-associated proteins, which can efflux sodium valproate back to the plasma from erythrocytes and result in an increased erythrocyte distribution of sodium valproate[25]. Therefore, it would be of great significance to study the effects of interaction between carbapenem antibiotics and sodium valproate on

hemolysis.

In summary, this is the first case report of ALF with TMA caused by sodium valproate, which is notable. However, there were some limitations to our study. Liver pathology was unavailable. Without results regarding ADAMTS13 activities or anti-ADAMTS13 antibodies, we found it difficult to distinguish between HUS and TTP in this patient. Establishing an animal model can facilitate further studies on pathogenesis and pathophysiological state.

CONCLUSION

ALF with TMA, which has not been reported before, is a fatal complication caused by sodium valproate. It is a disease with sudden onset and rapid progression, which needs great attention. A history of chronic HBV infection or combination therapy with sodium valproate and carbapenem may increase the risk of ALF. The combination therapy of PE, hemoperfusion, glucocorticoid, and supportive therapy is essential for TMA. However, it is not effective for all. For critically ill patients, organ transplantation should be considered first.

ACKNOWLEDGEMENTS

The authors would like to thank all researchers and study participants for their contributions.

REFERENCES

- 1 **Hanaya R**, Arita K. The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications. *Neurol Med Chir (Tokyo)* 2016; **56**: 205-220 [PMID: [26935782](#) DOI: [10.2176/nmc.ra.2015-0344](#)]
- 2 **Yamazaki S**, Watanabe T, Sato S, Yoshikawa H. Outcome of renal proximal tubular dysfunction with Fanconi syndrome caused by sodium valproate. *Pediatr Int* 2016; **58**: 1023-1026 [PMID: [26896192](#) DOI: [10.1111/ped.12956](#)]
- 3 **Nanau RM**, Neuman MG. Adverse drug reactions induced by valproic acid. *Clin Biochem* 2013; **46**: 1323-1338 [PMID: [23792104](#) DOI: [10.1016/j.clinbiochem.2013.06.012](#)]
- 4 **Romoli M**, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. *Curr Neuropharmacol* 2019; **17**: 926-946 [PMID: [30592252](#) DOI: [10.2174/1570159X17666181227165722](#)]
- 5 **Guo HL**, Jing X, Sun JY, Hu YH, Xu ZJ, Ni MM, Chen F, Lu XP, Qiu JC, Wang T. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. *Curr Pharm Des* 2019; **25**: 343-351 [PMID: [30931853](#) DOI: [10.2174/1381612825666190329145428](#)]
- 6 **Hebert SA**, Bohan TP, Erikson CL, Swinford RD. Thrombotic microangiopathy associated with Valproic acid toxicity. *BMC Nephrol* 2017; **18**: 262 [PMID: [28774273](#) DOI: [10.1186/s12882-017-0677-4](#)]
- 7 **Bruniera FR**, Ferreira FM, Savioli LR, Bacci MR, Feder D, Pereira EC, Pedreira ML, Peterlini MA, Perazzo FF, Azzalis LA, Rosa PC, Junqueira VB, Sato MA, Fonseca FL. Endothelial, renal and hepatic variables in Wistar rats treated with Vancomycin. *An Acad Bras Cienc* 2014; **86**: 1963-1972 [PMID: [25590732](#) DOI: [10.1590/0001-3765201420140204](#)]
- 8 **De Bus L**, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, Van Vlierberghe H. Severe drug-induced liver injury associated with prolonged use of linezolid. *J Med Toxicol* 2010; **6**: 322-326 [PMID: [20358416](#) DOI: [10.1007/s13181-010-0047-0](#)]
- 9 **Peng Y**, Li CY, Yang ZL, Shi W. Adverse reactions of vancomycin in humans: A protocol for meta-analysis. *Medicine (Baltimore)* 2020; **99**: e22376 [PMID: [32957416](#) DOI: [10.1097/MD.00000000000022376](#)]
- 10 **Vinh DC**, Rubinstein E. Linezolid: a review of safety and tolerability. *J Infect* 2009; **59** Suppl 1: S59-S74 [PMID: [19766891](#) DOI: [10.1016/S0163-4453\(09\)60009-8](#)]
- 11 **Bayram N**, Düzgöl M, Kara A, Özdemir FM, Devrim İ. Linezolid-related adverse effects in clinical practice in children. *Arch Argent Pediatr* 2017; **115**: 470-475 [PMID: [28895694](#) DOI: [10.5546/aap.2017.eng.470](#)]
- 12 **Bassett JT**, Rodriguez B, Mulligan L, Fontana RJ. Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation. *Epilepsy Behav Rep* 2019; **12**: 100342 [PMID: [31799506](#) DOI: [10.1016/j.ebr.2019.100342](#)]
- 13 **Danan G**, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. *Int J Mol Sci* 2015; **17**: 14 [PMID: [26712744](#) DOI: [10.3390/ijms17010014](#)]

- 14 **Trinka E**, Höfler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. *CNS Drugs* 2014; **28**: 623-639 [PMID: 24806973 DOI: 10.1007/s40263-014-0167-1]
- 15 U.S. National Library of Medicine. Valproic acid capsule drug label information, 2015 [cited 8 June 2020]. Database: DailyMed [Internet]. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c628829c-74de-485a-b6cb-42e1da894376>
- 16 **Koenig SA**, Buesing D, Longin E, Oehring R, Häussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Brückner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, Müller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. *Epilepsia* 2006; **47**: 2027-2031 [PMID: 17201699 DOI: 10.1111/j.1528-1167.2006.00846.x]
- 17 **Schmid MM**, Freudenmann RW, Keller F, Connemann BJ, Hiemke C, Gahr M, Kratzer W, Fuchs M, Schönfeldt-Lecuona C. Non-fatal and fatal liver failure associated with valproic acid. *Pharmacopsychiatry* 2013; **46**: 63-68 [PMID: 22915484 DOI: 10.1055/s-0032-1323671]
- 18 **Schulpis KH**, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S. Low serum biotinidase activity in children with valproic acid monotherapy. *Epilepsia* 2001; **42**: 1359-1362 [PMID: 11737173 DOI: 10.1046/j.1528-1157.2001.47000.x]
- 19 **Ghozzi H**, Hakim A, Sahnoun Z, Ben Mahmoud L, Atheymen R, Hammami S, Zeghal K. [Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses]. *Rev Neurol (Paris)* 2011; **167**: 600-606 [PMID: 21492891 DOI: 10.1016/j.neurol.2011.02.035]
- 20 **George JN**, Nester CM. Syndromes of thrombotic microangiopathy. *N Engl J Med* 2014; **371**: 654-666 [PMID: 25119611 DOI: 10.1056/NEJMra1312353]
- 21 **Wirtschafter E**, VanBeek C, Linhares Y. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature. *Exp Hematol Oncol* 2018; **7**: 14 [PMID: 29977661 DOI: 10.1186/s40164-018-0106-9]
- 22 **Daram SR**, Philipneri M, Puri N, Bastani B. Thrombotic thrombocytopenic purpura without schistocytes on the peripheral blood smear. *South Med J* 2005; **98**: 392-395 [PMID: 15813170 DOI: 10.1097/01.SMJ.0000136231.83564.F6]
- 23 **Chatzikonstantinou T**, Gavriilaki M, Anagnostopoulos A, Gavriilaki E. An Update in Drug-Induced Thrombotic Microangiopathy. *Front Med (Lausanne)* 2020; **7**: 212 [PMID: 32528969 DOI: 10.3389/fmed.2020.00212]
- 24 **König SA**, Knolle J, Friedewald S, Koelfen W, Longin E, Lenz T, Hannak D. Effects of valproic acid, carbamazepine, and phenobarbitone on the fatty acid composition of erythrocyte membranes in children. *Epilepsia* 2003; **44**: 708-711 [PMID: 12752471 DOI: 10.1046/j.1528-1157.2003.09802.x]
- 25 **Ogawa K**, Yumoto R, Hamada N, Nagai J, Takano M. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. *Epilepsy Res* 2006; **71**: 76-87 [PMID: 16806827 DOI: 10.1016/j.eplepsyres.2006.05.016]